Impact of Systemic Venous Congestion in Heart Failure

  • Matthias Dupont
  • Wilfried Mullens
  • W. H. Wilson Tang
Prevention of Heart Failure after Myocardial Infarction (Martin St. John Sutton, Section Editor)

Abstract

Systemic venous congestion is one of the hallmarks of the syndrome of heart failure that results from activation of different deleterious neurohormonal pathways. Apart from contributing to patients’ symptoms and hospital admissions, growing evidence suggests that congestion itself drives further heart failure progression. In addition, systemic venous congestion exerts detrimental effects on other organs (such as kidneys and liver) due to ineffective organ perfusion. Endothelial cell activation, altered ventricular geometry, and functional mitral insufficiency are among the proposed mechanisms. Diuretics and vasodilators remain the mainstay of treatment options, mostly because of poor understanding of the underlying cardiorenal mechanisms involved. Recently, ultrafiltration has emerged as an invasive treatment option in the setting of diuretic resistance. Congestion ideally should be prevented, often initially through water and salt restriction. Early detection, possibly with the help of novel implantable sensor technology, may allow for early detection and intervention long before overt congestion is established.

Keywords

Cardiorenal syndrome Venous congestion Diuretics Edema Heart failure Prevention Treatment Myocardial infarction Diagnostics Early detection 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary: HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:475–539.CrossRefGoogle Scholar
  2. 2.
    Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977–2016.PubMedCrossRefGoogle Scholar
  3. 3.
    Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157:99–104.PubMedCrossRefGoogle Scholar
  4. 4.
    Adams Jr KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Yu C-M, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Futcher PH, Schroeder HA. Studies on congestive heart failure, II: Impaired renal excretion of sodium chloride. Am J Med Sci. 1942;204:52–62.CrossRefGoogle Scholar
  7. 7.
    Braunwald E, Plauth Jr WH, Morrow AG. A method for the detection and quantification of impaired sodium excretion: results of an oral sodium tolerance test in normal subjects and in patients with heart disease. Circulation. 1965;32:223–31.PubMedGoogle Scholar
  8. 8.
    Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med. 1988;319:1065–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.PubMedCrossRefGoogle Scholar
  11. 11.
    Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–50.PubMedCrossRefGoogle Scholar
  13. 13.
    Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function. A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47:76–84.PubMedCrossRefGoogle Scholar
  14. 14.
    Hogg K, McMurray J. Neurohumoral pathways in heart failure with preserved systolic function. Prog Cardiovas Dis. 2005;47:357–66.CrossRefGoogle Scholar
  15. 15.
    Damman K, Voors AA, Hillege HL, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail. 2010;12:974–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Drazner MH, Rame JE, Stevenson LW, et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345:574–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med. 1986;314:1547–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Mullens W, Abrahams Z, Francis GS, et al. Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103(8):1113–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–57.PubMedCrossRefGoogle Scholar
  23. 23.
    Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronisation on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.PubMedCrossRefGoogle Scholar
  24. 24.
    Rosario LB, Stevenson LW, Solomon SD, et al. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol. 1998;32:1819–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Colombo PC, Banchs JE, Celaj S, et al. Endothelial cell activation in patients with decompensated heart failure. Circulation. 2005;111(1):58–62.PubMedCrossRefGoogle Scholar
  26. 26.
    • Ganda A, Onat D, Demmer RT, et al. Venous congestion and endothelial cell activation in acute decompensated heart failure. Curr Heart Fail Rep. 2010;7:66–74. This review highlights the current evidence and pathophysiologic mechanisms for endothelial cell activation as a consequence of venous congestion. PubMedCrossRefGoogle Scholar
  27. 27.
    Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol. 1931;72:49–61.PubMedGoogle Scholar
  30. 30.
    •• Damman K, Van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582–588. Together with reference 31, this article shifted attention from low cardiac output to venous congestion as THE most important hemodynamic cause of renal dysfunction in heart failure. This article demonstrates a correlation between increased CVP and impaired renal function in a broad spectrum of patients with cardiovascular disease. PubMedCrossRefGoogle Scholar
  31. 31.
    •• Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–596. Together with reference 30, this article shifted attention from low cardiac output to venous congestion as the most important hemodynamic cause of renal dysfunction in heart failure. This article points to CVP as the most important hemodynamic variable associated with worsening renal function. PubMedCrossRefGoogle Scholar
  32. 32.
    Testani JM, Khera AV, St John Sutton MG, et al. Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure. Am J Cardiol. 2010;105(4):511–6.PubMedCrossRefGoogle Scholar
  33. 33.
    • Mullens W, Abrahams Z, Skouri H, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:300–306. This study demonstrated a correlation between elevated intra-abdominal pressures and worsening renal function. This is a new concept, at least in heart failure patients. PubMedCrossRefGoogle Scholar
  34. 34.
    Mullens W, Abrahams Z, Francis GS, et al. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail. 2008;14(6):508–14.PubMedCrossRefGoogle Scholar
  35. 35.
    Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363(15):1419–28.PubMedCrossRefGoogle Scholar
  36. 36.
    Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000;109:109–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11:170–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Lau GT, Tan HC, Kritharides L. Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. Am J Cardiol. 2002;90:1405–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J. 2005;26:2232–7.CrossRefGoogle Scholar
  40. 40.
    Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884–8.PubMedCrossRefGoogle Scholar
  41. 41.
    • Chaudhry SI, Mattera JA, Curtis JP, et al. Telemonitoring in patients with heart failure. N Engl J Med. 2010;363:2301–2309. This trial, and the accompanying editorial, nicely point out the current limitations and requirements for optimal telemonitoring. PubMedCrossRefGoogle Scholar
  42. 42.
    • Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658–666. This recent study serves as proof of concept that early intervention, based on hemodynamic data, can avoid hospital admission due to ADHF. PubMedCrossRefGoogle Scholar
  43. 43.
    Bourge RC, Abraham WT, Adamson PB, et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51:1073–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure – activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6.PubMedGoogle Scholar
  45. 45.
    Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A(1) adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–53.PubMedCrossRefGoogle Scholar
  46. 46.
    Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–64.PubMedCrossRefGoogle Scholar
  47. 47.
    Agostoni P, Marenzi G, Lauri G, et al. A Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96(3):191–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.PubMedCrossRefGoogle Scholar
  49. 49.
    Vanderheyden M, Houben R, Verstreken S, et al. Continuous monitoring of intrathoracic impedance and right ventricular pressures in patients with heart failure. Circ Heart Fail. 2010;3(3):370–377.PubMedCrossRefGoogle Scholar
  50. 50.
    Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52(3):200–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Publication committee for the VMAC investigators. Intravenous neseritide versus nitroglycerin for treatment of decompensated congestive heart failure: the VMAC trial. JAMA. 2002;287:1531–40.CrossRefGoogle Scholar
  52. 52.
    Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625–33.PubMedCrossRefGoogle Scholar
  53. 53.
    Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–72.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Matthias Dupont
    • 1
  • Wilfried Mullens
    • 2
    • 3
  • W. H. Wilson Tang
    • 1
  1. 1.Department of Cardiovascular Medicine, Heart and Vascular InstituteCleveland ClinicClevelandUSA
  2. 2.Department of Cardiovascular MedicineZiekenhuis Oost LimburgGenkBelgium
  3. 3.School of Life SciencesTransnational University LimburgDiepenbeekBelgium

Personalised recommendations